Phone Number
(800) 210-7017
(800) 210-7017
PRP carries a favorable safety profile because you’re injecting the patient’s own blood components, but “favorable” isn’t “harmless,” and the difference shows up fast when patient selection gets lazy. Most adverse events are local and self-limited, but the serious ones (septic arthritis, nerve injury, vascular compromise) are catastrophic enough that screening, sterile technique, and image guidance aren’t optional. The clinician’s job is to separate the routine post-injection flare from the small set of conditions where PRP simply doesn’t belong.
PRP’s risk profile is dominated by mild, self-limited local reactions, but septic arthritis, nerve injury, and vascular complications remain rare catastrophic outcomes that demand sterile technique, image guidance, and disciplined screening for absolute contraindications like active infection, platelet dysfunction, and hematologic malignancy.
You should expect your patient to feel worse before they feel better, and that’s not a failure of the procedure, it’s the procedure working. PRP is intentionally pro-inflammatory in its early phase, so the soreness, swelling, and stiffness in the first 72 hours are the drug doing its job, not a complication. The job is teaching the patient which discomfort is normal and which symptoms mean “call the office now.”
The expected post-PRP course includes a soreness flare lasting one to three days, mild swelling and stiffness, and bruising at both the antecubital draw site and the injection site, with most patients returning to light activity within a few days and full activity within one to two weeks.
Catastrophic PRP complications are rare, but “rare” only matters until it’s your patient. The published literature shows a small handful of categories where serious harm has been documented, and each one maps to a specific failure of preparation, technique, or site selection. Knowing the categories is how you keep your numerator at zero.
Septic arthritis after intra-articular PRP is estimated at below 1 in 10,000 injections when sterile technique is observed, and the other documented serious events (nerve injury, vascular compromise, and rare reactions to processing additives like bovine thrombin or ACD-A) cluster in deep, vascular-rich, or neurologically adjacent sites where image guidance and sterile preparation are non-negotiable.
These aren’t the cases where you have a careful conversation and proceed with extra workup. These are the cases where you stop. An absolute contraindication means the procedure either cannot work biologically or the catastrophic risk crosses a line no reasonable clinician would step over.
Absolute contraindications to PRP include active local or systemic infection, platelet dysfunction syndromes such as critical thrombocytopenia or Bernard-Soulier disease, active hematologic malignancy, solid tumor at or adjacent to the injection site, and hemodynamic instability, with pregnancy treated as absolute by most practices due to the lack of safety data.
Relative contraindications are the gray zone, and they’re where most of the real clinical judgment lives. The procedure isn’t off the table, but going forward without modification is sloppy. Each scenario below has its own workup, washout, or counseling step before you put a needle in.
Relative contraindications require workup or protocol modification rather than refusal, including a target A1C below 7.5 to 8.0 for diabetics, a four to six week corticosteroid washout, baseline CBC verification of platelets above 100,000 to 150,000, and NSAID discontinuation for 5 to 7 days before and 2 to 4 weeks after injection.
This is the conversation people rush, and it’s the one that bites them. Anticoagulants and antiplatelets cut two ways at once: they raise bleeding risk during the procedure, and they directly compromise the platelet payload PRP is built to deliver. Every decision to hold or continue should be shared with the prescribing clinician and documented in the consent.
| Agent Class | Typical Pause | Why It Matters |
|---|---|---|
| Warfarin | Confirm in-range INR or coordinate brief hold | Hematoma risk at draw and injection sites |
| Direct oral anticoagulants (apixaban, rivaroxaban, dabigatran) | 24 to 48 hours, individualized by renal function | Bleeding risk in deep or vascular-rich sites |
| Low-dose aspirin (81 mg) | 7 to 10 days when safe; often continued for cardiac patients | Irreversibly blocks COX-1 and platelet aggregation |
| P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) | 5 to 7 days with cardiology approval | Stronger platelet blockade than aspirin |
Direct oral anticoagulants are typically paused 24 to 48 hours before PRP individualized to renal function, low-dose aspirin is held 7 to 10 days when cardiovascular risk allows, and P2Y12 inhibitors like clopidogrel and ticagrelor are held 5 to 7 days with cardiology approval, with every hold-or-continue decision shared with the prescriber and documented in the consent.
Infection is the one complication that can turn a low-risk biologic into a limb-threatening event, and the prevention strategy is discipline, not antibiotics. Prophylactic coverage doesn’t move the needle for clean procedures; sterile technique and a closed workflow do. Here’s how the steps line up.
Septic arthritis after intra-articular PRP is estimated at less than 1 in 10,000 to 1 in 50,000 injections when sterile technique is observed, and minimization depends on hand hygiene, sterile gloves, wide chlorhexidine-alcohol or povidone-iodine prep with proper dwell time, closed-system PRP processing, and patient counseling to distinguish expected post-injection flare from infection warning signs.
PRP isn’t a single product. The decisions made at the centrifuge (which cells stay in, which get spun out, how the platelets get activated) shape what the patient feels for the next week and how the tissue responds for the next several months. Matching preparation to indication is one of the highest-yield ways you have to keep flare tolerable while preserving the therapeutic effect.
Leukocyte-rich PRP produces stronger early flare and is preferred for chronic tendinopathies, leukocyte-poor PRP produces a milder post-injection course and is preferred for intra-articular use particularly in knee osteoarthritis, and platelet concentration targets cluster at 3 to 7 times baseline with substantially higher concentrations associated with paradoxically inhibitory effects rather than improved outcomes.
The procedure is the same, but the patient changes the math. Comorbidities shift PRP from a mechanical injection decision into a whole-patient calculation where infection risk, healing capacity, growth-factor signaling, and underlying disease activity all pull on the lever at once. The patients below need their own conversation, not the standard one.
Diabetes impairs healing and infection defense, prior cancer demands avoidance at or near the original site plus 2 to 5 years of remission and oncology clearance before PRP elsewhere, autoimmune diseases require controlled disease activity and tempered expectations, and immunosuppressed patients including transplant recipients and active chemotherapy patients usually require deferral or multidisciplinary review.
Consent isn’t a signature, it’s a documented conversation. The strongest defense against a complication going badly later is a record showing the patient understood the risks, the off-label status, the honest range of expected benefit, and the cost, before they ever sat on the table. Here’s the sequence that holds up.
Defensible PRP informed consent requires disclosure of all major risk categories, explicit acknowledgement of the off-label status for most musculoskeletal indications in the United States, honest range-bound benefit expectations with a typical four to twelve week response timeline, written financial terms, and procedure-specific documentation including the PRP system, leukocyte content, activation method, and image guidance used.
